c-Jun N-terminal kinases (JNKs) have been proposed as therapeutic targets in multiple pathologies, including cancer, inflammation and neuronal and metabolic diseases. SP-600125 is one of the first-generation reversible ATP-competitive inhibitors of JNK1/2/3 and has shown anticancer potential against leukemia, lung adenocarcinoma and pancreatic cancer, among others.